Business Overview: Achieve Life Sciences, Inc. (NASDAQ: ACHV)

---

Executive Summary

Achieve Life Sciences, Inc. is a clinical-stage biopharmaceutical company developing cytisinicline, a plant-derived nicotinic receptor partial agonist, as a treatment for smoking cessation and nicotine dependence, including e-cigarette/vaping cessation. Cytisinicline, derived from the seeds of the Cytisus laburnum plant, has a decades-long history of use as a smoking cessation aid in Central and Eastern Europe under other brand names, and Achieve is developing it for FDA approval and commercialization in the United States and other major markets, positioning it as a potential successor to Pfizer's troubled Chantix (varenicline).

---

1. Core Business Model & How They Work

Achieve's business model centers on advancing cytisinicline through U.S. clinical trials and regulatory approval, leveraging decades of international real-world use as supportive evidence, with the goal of commercializing it directly or through a larger pharmaceutical partner.

[ Cytisinicline (decades of Eastern European use) ]
     ➡ [ U.S. Phase 3 Clinical Trials: ORCA-2, ORCA-3 (Smoking Cessation) ]
     ➡ [ ORCA-V1 (Vaping/E-Cigarette Cessation) ]
     ➡ [ FDA New Drug Application & Approval ]
     ➡ [ Commercialization (Direct or via Pharma Partner) ]

Key Operational Drivers

1. Repurposing a Proven Molecule for the U.S. Market: Rather than developing a novel compound from scratch, Achieve is bringing an established, long-used smoking cessation therapy through the U.S. regulatory pathway, potentially reducing development risk relative to a first-in-class molecule.
2. Positioning Against a Weakened Incumbent: Pfizer's Chantix (varenicline) faced major supply disruptions and market withdrawal issues related to nitrosamine impurity contamination, creating a market opening for a differentiated, well-tolerated alternative like cytisinicline.
3. Expansion into Vaping Cessation: Beyond traditional cigarette smoking cessation, Achieve is studying cytisinicline for e-cigarette/vaping cessation (ORCA-V1), addressing a large and growing at-risk population, particularly among younger users, with no FDA-approved therapy currently available for this specific indication.

---

2. Pipeline

---

3. Competitive Landscape

                Prescription Smoking Cessation Drugs      Nicotine Replacement Therapy (NRT)
                              │                                     │
      Chantix (Pfizer,        │                          Nicorette, NicoDerm
      varenicline; supply/    │                          (GSK/Haleon) — patches,
      safety issues) ─────────┤                           gum, lozenges (OTC)
      Zyban/Bupropion ────────┤                                    │
                              │                                    │
      ────────────────────────┼─────────────────────────────────────
                              │
                    Cytisinicline (Achieve Life Sciences, ACHV)
                 (plant-derived, decades of European use, differentiated
                  safety profile, targeting both smoking and vaping cessation)

Competitors by Domain

Prescription Smoking Cessation

• Key Competitors: Pfizer's Chantix (varenicline), which has faced significant supply chain and safety-related setbacks (nitrosamine contamination recalls), and bupropion (Zyban), an older antidepressant also approved for smoking cessation.
• Dynamics: Chantix's manufacturing and safety difficulties have created a real market opportunity for cytisinicline to establish itself as a well-tolerated, effective alternative, assuming Achieve can achieve FDA approval and commercial-scale manufacturing and distribution.

Nicotine Replacement Therapy (NRT)

• Key Competitors: GSK/Haleon's Nicorette and NicoDerm product lines (over-the-counter patches, gum, lozenges).
• Dynamics: NRT products are widely available OTC and represent the most common smoking cessation aid, but generally show lower quit rates than prescription options like varenicline or cytisinicline in clinical studies, positioning Achieve's product as a differentiated, potentially more effective prescription alternative.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Decades of real-world safety data from European use: A long history of use outside the U.S. under other brand names provides supportive clinical and safety evidence uncommon for a "new" U.S. drug candidate.
• Differentiated safety profile versus Chantix: Positioned to avoid the nitrosamine contamination and associated supply disruptions that have plagued Pfizer's varenicline franchise.
• First-mover potential in vaping cessation: With no FDA-approved vaping cessation therapy currently on the market, cytisinicline could become the first approved option in a fast-growing category of need, particularly among younger populations.

Strategic Risks & Vulnerabilities

1. Regulatory approval risk: Despite supportive Phase 3 data, FDA approval and the specific labeling ultimately granted remain uncertain until final regulatory review is complete.
   • Mitigation Strategy: Leverage the extensive existing safety database and positive pivotal trial results to support a robust regulatory submission.
2. Commercial launch and manufacturing execution risk: As a smaller company, Achieve will likely need manufacturing, sales, and distribution partnerships or significant capital investment to commercialize successfully at scale.
   • Mitigation Strategy: Pursue partnership discussions with larger pharmaceutical companies with existing commercial infrastructure in the smoking cessation and broader respiratory/CNS space.
3. Potential Chantix market re-entry or new competitive entrants: If Pfizer resolves its manufacturing issues and Chantix returns to market at scale, or new competitors emerge, cytisinicline's competitive positioning could be challenged.
   • Mitigation Strategy: Emphasize cytisinicline's differentiated efficacy, tolerability, and dual smoking/vaping cessation positioning to maintain differentiation regardless of Chantix's market status.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Achieve Life Sciences is positioning cytisinicline as a differentiated, well-tolerated smoking and vaping cessation therapy at a moment when the long-dominant prescription incumbent, Pfizer's Chantix, has been weakened by manufacturing and safety-related setbacks. Decades of international use provide an unusually rich safety dataset for a company at this stage of U.S. regulatory development.

The company's central strategic question is whether it can successfully navigate FDA approval and then either build out commercial infrastructure or secure a strong pharmaceutical partnership to reach the large population of smokers and vapers seeking cessation support, capturing the market opportunity created by Chantix's struggles before competitors or a reinvigorated incumbent can respond.